US Defense finishes latest research on Immuron’s Travelan®
Immuron Limited (ASX:IMC | NASDAQ:IMRN) announced today its three US Defense Health funded research projects on Travelan have been successfully completed.
The studies, commissioned by the US Department of Defense (DoD), were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.
Now the company will progress with an evaluation of the therapeutic efficacy of Travelan in pre-clinical Shigellosis studies.
“Travelan has been designed to target selected surface antigens from the most common strains of Enterotoxigenic E. coli (ETEC), bacteria which play a dominant and causative role in Travellers’ diarrhea,” Immuron CEO Dr Jerry Kanellos said.
“The work completed at the US Armed Forces Research Institute of Medical Sciences, US Naval Medical Research Center and the Walter Reed Army Institute of Research has highlighted that in laboratory testing Travelan was effective across all strains and species of enteropathogenic bacteria tested.
“The specificity of antibodies incorporated into Travelan cross-react with multiple Campylobacter, ETEC and Shigella strains. The product is truly cross-reactive indicating a substantially broader spectrum of antimicrobial action than previously reported. This new research offers a pathway to further testing which could lead to a major new preventative modality for the US DoD.”
Of course, it should be noted that Immuron is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.
The studies so far — completed at US Armed Forces Research Institute of Medical Sciences (AFRIMS), US Naval Medical Research Center (NMRC) and the Walter Reed Army Institute of Research (WRAIR) — have highlighted that in laboratory testing Travelan was effective across all strains and species of enteropathogenic bacteria.
The three completed studies commissioned by the DoD are as follows:
- AFRIMS Study demonstrated Travelan effectively reacted to 180 clinical isolates tested from personnel infected with Campylobacter, Enterotoxigenic Escherichia coli (ETEC) and Shigella. This first study involving Travelan® was performed at the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences (AFRIMS). The findings of this comprehensive study were reported by the company in January 2018.
- NMRC Study demonstrated Travelan bound to and neutralized key components used by the ETEC bacteria to attach to host cells and cause disease. This study was performed by the Department of Enteric Infections, US Naval Medical Research Center (NMRC) and reported that Travelan was specifically shown to;
- React with the major colonization factor antigens.
- Bind to key fimbrial proteins which are used by the bacteria to attach to host cells and cause disease.
- Inhibit the bacteria binding and causing cell hemagglutination.
- React with the heat labile enterotoxin sub-unit B (LTB) produced by Vibrio spp. (the causative agent of cholera).
- WRAIR Study demonstrated Travelan bound to similar targets present on ETEC and Shigella bacteria. The Department of Enteric Infections, Bacterial Diseases Branch at the Walter Reed Army Institute of Research, assessed Travelan immune-reactivity with ETEC and Shigella antigens, which demonstrated they were reacting to common bacterial antigens.
The global burden of diarrhoeal diseases like Shigella dwarfs any of the more complex diseases seen in gastroenterology clinics. There are an estimated 1.5 billion episodes of diarrhoea worldwide each year, and these episodes result in the deaths of approximately 2.2 million people — mostly children in developing countries.
Shigella in particular is estimated to cause 80–165 million cases of disease worldwide, resulting in 600,000 deaths annually — and is particularly prevalent in both sub-Saharan Africa and South Asia. For the US DoD, a preventative treatment that protects against enteric diseases, specifically Shigella, is a high priority objective, particularly with its strong presence in south-east Asia.
IMC has proprietary vaccines it uses to immunise cows which target specific bacteria, toxins or spores — so when it comes to calving time, the end result is colostrum that is full of antibodies it needs to make its specific, targeted products.
To follow these successful studies, IMC is now pursuing a research agreement with the CSIRO to develop Shigella specific anti-microbial therapeutics for preclinical evaluation.
The company has also just submitted a grant funding proposal for the development of a therapeutic product against campylobacter and other enteric pathogens, jointly with the campylobacter research team at the NMRC.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.